share_log

6-K: Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024

6-K: Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024

诺和诺德 | 6-K：诺和诺德 -截至2024年4月26日的诺和诺德公司投票权和股本总数
美股sec公告 ·  04/26 08:43
Moomoo AI 已提取核心信息
On April 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced an update to its share capital and voting rights structure as required by Section 32 of the Danish Capital Markets Act. The update followed changes that occurred within the month, as referenced in Company Announcement no 32/2024 dated April 24, 2024. The total number of shares now stands at 4,465,000,000, with a share capital of DKK 446,500,000. The A shares, each carrying 100 votes, total 1,074,872,000, while the B shares, with 10 votes each, total 3,390,128,000. This results in a total of 141,388,480,000 voting rights. Treasury shares are accounted for but do not carry voting rights at general meetings. Novo Nordisk, founded in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases and is present in 80 countries, marketing its products in approximately 170 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
On April 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced an update to its share capital and voting rights structure as required by Section 32 of the Danish Capital Markets Act. The update followed changes that occurred within the month, as referenced in Company Announcement no 32/2024 dated April 24, 2024. The total number of shares now stands at 4,465,000,000, with a share capital of DKK 446,500,000. The A shares, each carrying 100 votes, total 1,074,872,000, while the B shares, with 10 votes each, total 3,390,128,000. This results in a total of 141,388,480,000 voting rights. Treasury shares are accounted for but do not carry voting rights at general meetings. Novo Nordisk, founded in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases and is present in 80 countries, marketing its products in approximately 170 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
2024年4月26日，全球领先的医疗保健公司诺和诺德A/S宣布按照《丹麦资本市场法》第32条的要求更新其股本和投票权结构。该更新是在本月内发生的变化之后进行的，如2024年4月24日第32/2024号公司公告所述。目前股票总数为44.65亿股，股本为44.65亿丹麦克朗。每股拥有100张选票的A股总票数为1,074,872,000张，而B股每股有10张选票，总票数为3,390,128,000张。这导致总共有141,388,48万张投票权。库存股已入账，但在股东大会上不具有投票权。诺和诺德成立于1923年，总部位于丹麦，专注于战胜严重的慢性病，业务遍及80个国家，产品销往约170个国家。该公司的B股在哥本哈根纳斯达克上市，其ADR在纽约证券交易所上市，股票代码为NVO。
2024年4月26日，全球领先的医疗保健公司诺和诺德A/S宣布按照《丹麦资本市场法》第32条的要求更新其股本和投票权结构。该更新是在本月内发生的变化之后进行的，如2024年4月24日第32/2024号公司公告所述。目前股票总数为44.65亿股，股本为44.65亿丹麦克朗。每股拥有100张选票的A股总票数为1,074,872,000张，而B股每股有10张选票，总票数为3,390,128,000张。这导致总共有141,388,48万张投票权。库存股已入账，但在股东大会上不具有投票权。诺和诺德成立于1923年，总部位于丹麦，专注于战胜严重的慢性病，业务遍及80个国家，产品销往约170个国家。该公司的B股在哥本哈根纳斯达克上市，其ADR在纽约证券交易所上市，股票代码为NVO。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息